Patent ID: 8906954

Claim:
A method of treating T-cell lymphoma or leukemia in a mammal in need thereof, comprising administering to the mammal a pharmaceutical composition comprising: (a) a therapeutically effective amount of a compound of Formula B: wherein: R 1 is —C(═O)NHOH; X 2 is a bond, —C 1 -C 6 alkylene-, —C 2 -C 6 alkenylene-, —C 2 -C 6 alkynylene-, —C 1 -C 6 heteroalkylene-, C 1 -C 6 fluoroalkylene, C 2 -C 6 fluoroalkenylene, C 1 -C 6 haloalkylene, C 2 -C 6 haloalkenylene, —C 1 -C 6 alkylene-O—, —C 1 -C 3 alkylene-O—C 1 -C 3 alkylene-, —C 1 -C 6 alkylene-NH—, —C 1 -C 3 alkylene-NH—C 1 -C 3 alkylene-, —C 1 -C 6 alkylene-C(═O)NH—, —C 1 -C 3 alkylene-C(═O)NH—C 1 -C 3 alkylene-, —C 1 -C 6 alkylene-NHC(═O)—, —C 1 -C 3 alkylene-NHC(═O)—C 1 -C 3 alkylene-, —C 1 -C 6 alkylene-S—, —C 1 -C 3 alkylene-S—C 1 -C 3 alkylene-, —C 1 -C 6 alkylene-S(═O)—, —C 1 -C 3 alkylene-S(═O)—C 1 -C 3 alkylene, —C 1 -C 6 alkylene-S(═O) 2 —, —C 1 -C 3 alkylene-S(═O) 2 —C 1 -C 3 alkylene,-C(═O)—, or —C(═O)—C 1 -C 6 alkylene; R 2 is a substituted or unsubstituted group selected from aryl, heteroaryl, C 3 -C 10 cycloalkyl, and C 2 -C 10 heterocycloalkyl; where if R 2 is substituted, then R 2 is substituted with 1, 2, or 3 groups selected from among halogen, C 1 -C 6 alkoxy, C 1 -C 6 fluoroalkoxy, aminoC 1 -C 6 alkoxy, C 1 -C 3 alkylaminoC 1 -C 3 alkoxy, hydroxyC 1 -C 3 alkylaminoC 1 -C 3 alkoxy, C 2 -C 8 heterocycloalkylC 1 -C 3 alkoxy, C 2 -C 8 heterocycloalkylC 1 -C 2 alkyl, —CN, —NO 2 , —CO 2 R 10 , —C(═O)R 11 , —S—R 11 , —S(═O)—R 11 , —S(═O) 2 —R 11 , —NR 10 C(═O)—R 11 , —C(═O)N(R 10 ) 2 , —S(═O) 2 N(R 10 ) 2 , —NR 10 S(═O) 2 —R 11 , —OC(═O)N(R 10 ) 2 , —NR 10 C(═O)O—R 11 , —OC(═O)O—R 11 , —NHC(═O)NH—R 11 , —OC(═O)—R 11 , —N(R10) 2 , —C 1 -C 2 alkylN(R 10 ) 2 , C 1 -C 6 alkyl, C 1 -C 6 fluoroalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 heteroalkyl, C 3 -C 8 cycloalkyl, substituted or unsubstituted C 2 -C 10 heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl; R 10 is hydrogen, or a substituted or unsubstituted group selected from among C 1 -C 6 alkyl, C 1 -C 6 fluoroalkyl, C 1 -C 6 heteroalkyl, C 3 -C 8 cycloalkyl, C 2 -C 8 heterocycloalkyl, aryl, and heteroaryl; R 11 is a substituted or unsubstituted group selected from among C 1 -C 6 alkyl, C 1 -C 6 fluoroalkyl, C 3 -C 8 cycloalkyl, C 2 -C 8 heterocycloalkyl, aryl, and heteroaryl; each R 3 is independently hydrogen, substituted or unsubstituted C 1 -C 6 alkyl, substituted or unsubstituted C 2 -C 6 alkenyl, substituted or unsubstituted C 2 -C 6 alkynyl, substituted or unsubstituted C 1 -C 6 alkoxy, substituted or unsubstituted C 1 -C 6 fluoroalkoxy, substituted or unsubstituted C 1 -C 6 heteroalkyl, substituted or unsubstituted phenyl, or C 1 -C 6 aminoalkyl; or a pharmaceutically acceptable salt, pharmaceutically acceptable N-oxide, pharmaceutically active metabolite, or pharmaceutically acceptable solvate thereof; and (b) a pharmaceutically acceptable diluent, excipient, or carrier.